AIM
CRL icon

Axiom Investment Management’s Charles River Laboratories CRL Stock Holding History

Axiom Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,696
Closed -$241K – 262
2019
Q2 		$241K Buy
+1,696
New +$230K 0.04% 325

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Axiom Investment Management's CRL Position: Q3 2019 in Review

Axiom Investment Management sold out of Charles River Laboratories (CRL) in Q3 2019, closing a stake of 1,696 shares — an estimated $241K sold.

Axiom Investment Management first reported a position in CRL in Q2 2019 and held it in 1 quarter. The position peaked at $241K in Q2 2019. 396 funds tracked by Wall St. Rank hold CRL as of Q3 2019.

  • Axiom Investment Management reported no remaining Charles River Laboratories position as of Q3 2019 after selling out during the quarter.
  • Axiom Investment Management sold 1,696 Charles River Laboratories shares in Q3 2019, an estimated $241K.
  • Axiom Investment Management first reported a position in Charles River Laboratories in Q2 2019 and held it in 1 quarter.
  • Axiom Investment Management's Charles River Laboratories position peaked at $241K in Q2 2019.
  • 396 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2019.

Based on Axiom Investment Management's 13F filing for Q3 2019, filed 16 Mar 2021.